BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28975241)

  • 1. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
    Kernan WN; Viscoli CM; Dearborn JL; Kent DM; Conwit R; Fayad P; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH;
    JAMA Neurol; 2017 Nov; 74(11):1319-1327. PubMed ID: 28975241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
    Yaghi S; Furie KL; Viscoli CM; Kamel H; Gorman M; Dearborn J; Young LH; Inzucchi SE; Lovejoy AM; Kasner SE; Conwit R; Kernan WN;
    Circulation; 2018 Jan; 137(5):455-463. PubMed ID: 29084736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
    Kernan WN; Viscoli CM; Furie KL; Young LH; Inzucchi SE; Gorman M; Guarino PD; Lovejoy AM; Peduzzi PN; Conwit R; Brass LM; Schwartz GG; Adams HP; Berger L; Carolei A; Clark W; Coull B; Ford GA; Kleindorfer D; O'Leary JR; Parsons MW; Ringleb P; Sen S; Spence JD; Tanne D; Wang D; Winder TR;
    N Engl J Med; 2016 Apr; 374(14):1321-31. PubMed ID: 26886418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
    Spence JD; Viscoli CM; Inzucchi SE; Dearborn-Tomazos J; Ford GA; Gorman M; Furie KL; Lovejoy AM; Young LH; Kernan WN;
    JAMA Neurol; 2019 May; 76(5):526-535. PubMed ID: 30734043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
    Young LH; Viscoli CM; Curtis JP; Inzucchi SE; Schwartz GG; Lovejoy AM; Furie KL; Gorman MJ; Conwit R; Abbott JD; Jacoby DL; Kolansky DM; Pfau SE; Ling FS; Kernan WN;
    Circulation; 2017 May; 135(20):1882-1893. PubMed ID: 28246237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
    Young LH; Viscoli CM; Schwartz GG; Inzucchi SE; Curtis JP; Gorman MJ; Furie KL; Conwit R; Spatz ES; Lovejoy A; Abbott JD; Jacoby DL; Kolansky DM; Ling FS; Pfau SE; Kernan WN;
    Circulation; 2018 Sep; 138(12):1210-1220. PubMed ID: 29934374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
    Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb PA; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN;
    Am Heart J; 2014 Dec; 168(6):823-9.e6. PubMed ID: 25458644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to study drug in a stroke prevention trial"?>.
    Kiran A; Viscoli CM; Furie KL; Gorman M; Kernan WN
    J Stroke Cerebrovasc Dis; 2020 Oct; 29(10):105048. PubMed ID: 32912514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
    Inzucchi SE; Viscoli CM; Young LH; Furie KL; Gorman M; Lovejoy AM; Dagogo-Jack S; Ismail-Beigi F; Korytkowski MT; Pratley RE; Schwartz GG; Kernan WN;
    Diabetes Care; 2016 Oct; 39(10):1684-92. PubMed ID: 27465265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
    Spence JD; Viscoli C; Kernan WN; Young LH; Furie K; DeFronzo R; Abdul-Ghani M; Dandona P; Inzucchi SE
    Diabetes Obes Metab; 2022 Jun; 24(6):1150-1158. PubMed ID: 35253334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
    Viscoli CM; Inzucchi SE; Young LH; Insogna KL; Conwit R; Furie KL; Gorman M; Kelly MA; Lovejoy AM; Kernan WN;
    J Clin Endocrinol Metab; 2017 Mar; 102(3):914-922. PubMed ID: 27935736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.
    Furie KL; Viscoli CM; Gorman M; Ford GA; Young LH; Inzucchi SE; Guarino PD; Lovejoy AM; Conwit R; Tanne D; Kernan WN;
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):21-27. PubMed ID: 28939682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
    Kernan WN; Inzucchi SE; Viscoli CM; Brass LM; Bravata DM; Shulman GI; McVeety JC; Horwitz RI
    Stroke; 2003 Jun; 34(6):1431-6. PubMed ID: 12730556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk.
    Viscoli CM; Kent DM; Conwit R; Dearborn JL; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH; Kernan WN;
    Stroke; 2019 Jan; 50(1):95-100. PubMed ID: 30580725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
    Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
    Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone.
    Inzucchi SE; Furie KL
    J Diabetes; 2016 Sep; 8(5):607-9. PubMed ID: 27125599
    [No Abstract]   [Full Text] [Related]  

  • 18. Taking care of volunteers in a stroke trial: a new assisted-management strategy.
    Stuart AC; Sico JJ; Viscoli CM; Tayal AH; Inzucchi SE; Ford GA; Furie KL; Cote R; Spence JD; Tanne D; Kernan WN
    Stroke Vasc Neurol; 2016 Sep; 1(3):108-114. PubMed ID: 28959471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
    Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
    Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.